Tiziana To Treat Multiple Sclerosis Patient With Nasal Administration of Foralumab

The FDA has allowed evaluation of Tiziana Life Sciences Plc's TLSA nasal administration with foralumab in a secondary progressive multiple sclerosis (SPMS) patient at the Brigham and Women's Hospital (BWH), Harvard University.

• The patient will be treated under an Individual Patient Expanded Access IND.
• The treatment is planned to start in the second quarter of this year and will continue for six months.
• Investigators will follow this patient with detailed routine safety, neurological imaging, and PET studies to evaluate microglial imaging.
• Previously, Tiziana completed a Phase 1 trial of multiple ascending doses once a day, dosing for five consecutive days with nasally administered Foralumab in healthy subjects.
• The treatment was well-tolerated with no drug-related safety issues reported at any dose up to 250 mg of the quantities.
• Earlier today, the company announced a controlled Phase 2 trial in Brazil for foralumab in moderate to severe hospitalized COVID-19 patients.
• Price Action: TLSA shares are trading 7.9% higher at $2.86 in market hours on the last check Tuesday.